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Intensiﬁcation of intra-arterial chemotherapy with high-dose cisplatin and concomitant reduction of toxicity under the
conditions of the head and neck was aimed at by combination of antineoplastic activity and embolizing effect in the same
pharmacon. A cisplatin suspension in normal saline (5 mg in 1 ml) with precipitation of microembolizing cisplatin crystals was
prepared. No additional pharmacons. Cisplatin dosage was 150 mg m
72, maximum absolute dose 300 mg, maximum amount
of ﬂuid 60 ml. Thirty patients (UICC-Classiﬁcation of tumours: I/2 patients, II/6, III/2; IV/20) were treated in a neoadjuvant
setting with superselective chemoembolization using the cisplatin suspension. A control group (n=30) with the same tumour
and nodal staging was treated with a usual cisplatin solution (150 mg m
72 dissolved in 500 ml saline). In both groups, parallel
intravenous infusion of sodium thiosulphate (9 g m
72). Endpoints were toxicity and response. Continuation of treatment by
surgery or radiation. Overall remission was 70% in the study group and 46.7% in the control group after one cycle
respectively. Systemic side-effects were very low (grade I WHO) in both groups. Side-effects were found to be similar to
post-embolization syndrome (swelling, mild to moderate pain, leucocytosis without fever) in the study group.
Chemoembolization in the head and neck area can be carried out routinely using this method.
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Regional chemotherapy via a tumour-feeding artery achieves
higher drug exposure at the target site than with corresponding
systemic exposure and, therefore, has the possibility of generat-
ing higher therapeutic response without jeopardizing tolerance.
In head and neck squamous cell carcinoma (SCC) patients,
Robbins et al (1994) found a maximum tolerated dose of
intra-arterially delivered cisplatin of 150 mg m
72. Cisplatin was
chosen because sodium thiosulphate can be used as systemic
antagonist. If thiosulphate circulates intravenously, cisplatin
becomes chelated and inactivated (Pfeiﬂe et al, 1985). By this
method, plasma clearance is increased and drug targeting
becomes still higher. Sensitive compartments, such as the bone
marrow, gut, and kidneys are protected from the toxic effect
of the drug. Using modern small catheter systems via the
femoral artery, it was possible to infuse the antineoplastic drug
superselectively (mainly into the lingual or facial artery). These
small vessels have a low ﬂow (about 120 ml min
71) which
additionally raises drug targeting. This therapeutic approach in
head and neck SCC showed good results with respect to
response and toxicity (n=4300 patients (Kova ￿cs et al, 1999;
Robbins et al, 2000). Another method of increasing the regional
advantage is the reduction or stop of blood ﬂow using micro-
capsules (Kato et al, 1996) or embolizing agents (Araki et al,
1989) resulting in longer tumour residence time, enhancement
of ﬁrst-pass extraction of the drug, and also hypoxic necrosis
which is intended. Embolization with encoated drug microcap-
sules or mixtures of drugs and embolizing agents were mainly
used in liver tumours because the liver is capable of compensat-
ing local necrosis due to the fact that most of the metastases
gain their blood supply via the hepatic artery (Breedis and
Young, 1954) while the rest of tissue is nourished by the portal
vein. Besides the drawback of a complicated technical produc-
tion of embolizing agents, there are extreme obstacles
concerning this method of a complete temporary halt of blood
ﬂow in the head and neck area: intolerable local necrosis and
danger to eyes and nerve ganglions via anastomoses. Due to
these facts, use of chemoembolization was casual in the head
and neck region to date.
In this study, a new dosage format of cisplatin is introduced
combining the advantages described above (high dose, emboliza-
tion, high response, low toxicity, use of antagonist) without the
drawbacks.
MATERIALS AND METHODS
Preparation of an aqueous crystal suspension of cisplatin
for intra-arterial application
Cisplatin (medac GmbH, Hamburg, Germany) is available in
brown glass vials containing a sterile yellowish-white lyophi-
lized powder with 50 mg cisplatin (=pharmacon), 450 mg
sodium chloride, 500 mg mannitol and hydrochloric acid
(=adjuncts).
The individual patient dosage is 150 mg m
72 (Robbins et al,
1994). Body surface is calculated by the empirical formula of Du
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2 refer-
ring to 300 mg cisplatin.
The cisplatin suspensions were prepared individually at the
centralized preparation area for cytotoxic drugs at the Department
of Pharmacy at Johann Wolfgang Goethe-University Medical
School. They were prepared under aseptic conditions using a verti-
cal laminar airﬂow work bench (according to DIN 12950) as well
as a weight controlled preparation software (Cypro 2.0, ars phar-
maceutica Gesellschaft fu ¨r klinisches Wissenschaftsmanagement
und Softwarelo ¨sungen mbH, Hamburg, Germany)
The lyophilized drug was reconstituted with 0.9% sodium chlor-
ide (Isotone Kochsalzlo ¨sung, Braun Melsungen AG, Melsungen,
Germany) leading to a yellow 10 ml mixture with a ﬁnal concen-
tration of 5 mg ml
71. The mixture was shaken until the powder
was suspended without macroscopically visible clumps. The
suspension of the needed number of vials was transferred with a
cannula (18G) into two 50 ml disposable sterile syringes (Perfusion
Plastipak, Becton Dickinson, Heidelberg, Germany). The syringes
were covered for light protection. Although physicochemical data
for cisplatin solutions indicates a stability up to 28 days (Trissel,
1998), it was decided to set the maximal expiration time to 8 h
at room temperature to limit non reproducible crystal growth.
The ready-to-use syringes were labelled with the patients name,
dosage, administration day, expiration time and the note ‘please
shake before administration’.
Pharmacological features of the aqueous crystal suspension
of cisplatin
The preparation method results in a monocomponent, a highly
concentrated aqueous suspension of cisplatin with precipitation of
crystals. The physicochemical properties (e.g.: PtPt distances, mole-
cular vibration analyses) of cisplatin crystals which did form in
frozen solutions have been previously described elsewhere (Milburn
and Truter, 1966). The stability of the cisplatin complex is pharma-
cologically assured in a suspension because sodium chloride is
solved in a high concentration in this dosage format. The resulting
ﬂuid is a 5.4% sodium chloride solution. Hypertonic sodium chloride
solutions reportedly do not have effect on pharmacokinetics of
cisplatin (medac, 2000). The osmolality is supposedly higher than
in an aqueous solution (about 285 mOsm kg
71 (McEvoy, 1991))
but cannot be measured exactly because of the presence of crystalline
precipitates. Theoretic osmolality of the described suspension as
calculated approximately is 2130 mOsm kg
71. Microscopic assess-
ment of particle diameters in the aqueous crystal suspension of
cisplatin showed rod-shaped crystals measuring 368 mm; regular
clumping of these crystals formed particles measuring 30650 mm
(Figures 1 and 2). Ratio of small to large particles was 100/1. In solu-
tions where precipitates did form, redissolution occurred very slowly
with warming back to room temperature (Greene et al, 1979). At
408C, the time of redissolution was about 20 to 30 min (Kristjansson
et al, 1988).
Patients and study design
In the period between May 2000 and March 2001, 30 Patients with
histologically proven, previously untreated primary SCC of the oral
cavity and the oropharynx were examined (males/females ratio=22/
8; mean age: 60.2+11.5 years; grading II/27, III/3; UICC stages I/2,
II/6, III/2, IV/20). The performance status (ECOG (Oken et al,
1982)) of the patients, distribution of tumour sizes and regional
lymph node classiﬁcation according to UICC (Sobin and Witte-
kind, 1997) were noted (Table 1). Routine pretherapeutic staging
procedures included palpation, ultrasound, computed tomography
and magnet resonance tomography for diagnostics of neck lymph
nodes as well as positron emission tomography for detection of
secondary tumours, neck lymph node affection and distant metas-
tases. Positron emission tomography was decisive for staging.
Ethical approval was given by the local ethical committee.
Informed consent was obtained prior to the onset of chemotherapy
and all other therapeutic procedures (e.g.: operation, chemoradia-
tion). The only exclusion criterion was the presentation of a
heavy renal insufﬁciency. All patients took part in a phase II study
with a novel concept of integrating induction therapy with intra-
arterial cisplatin, radical surgery with neck dissection and
combined weekly docetaxel with radiation to the primary site
and neck (Kova ￿cs et al, 2001).
Every patient was treated with one cycle of intra-arterial high-dose
chemotherapy in a neoadjuvant setting. Because surgery was consid-
ered an important modality of treatment, complete remission was not
necessarily aimed at. Regular repetitions of cycles striving at that aim
seemed to be too straining for the patients who should undergo a
multimodality treatment. In cases of partial remissions after the ﬁrst
cycle, the cycles could be repeated maximally twice, to avoid the
development of resistant cell lines. Routine laboratory checks were
made on alternate days and compared to pretherapeutic values.
The side effects of the cycles according to WHO (Miller et al, 1981)
were noted. It was decided to stop the study in case of grade III
and IV toxicity. Patients were assessed for local response 3–4 weeks
later. The dimension of response was assessed clinically (by inspec-
tion and palpation) and by CT examination after the ﬁrst cycle.
The remission degrees were deﬁned as follows: CR=complete remis-
sion, a complete disappearance of local tumour mass; PR=partial
remission, a partial reduction of local tumour mass of more than
50%; SD=stable disease, a partial reduction of local tumour mass
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Figure 1 Backlit photography of a drop (1267 mm) of the aqueous
cisplatin suspension on a slide showing the larger crystalline particles.
Figure 2 Microscopic photography of the aqueous cisplatin suspension;
the crystals are birefringent (2006).
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(2), 196–202of less than 50% or stability of local tumour mass; PD=progressive
disease, growth of the tumour 425%. The patients were scheduled
for surgery if they were in a general state where the operation should
be compatible with life or resection would not threaten vital organs.
This judgement was dependent on medical and anaesthesiological
examination carried out before the start of any treatment. The
patients not treated by surgery were to undergo radiation or chemor-
adiation therapy.
Thirty patients who had been treated with a cisplatin solution in
the period between February 1999 and April 2000 served as control
group. Matched pairs were established concerning distribution of
pre-treatment tumour and nodal classiﬁcation. Histologically
proven diagnosis in all cases has been previously untreated primary
SCC of the oral cavity and the oropharynx. The males/females ratio
was 20/10; mean age: 61.6+8.8 years; grading II/26, III/4; UICC
stages I/2, II/6, III/2, IV/20. The performance status (ECOG) of
the patients also was comparable to the other group (Table 1).
They have been accrued for the same multimodality treatment.
End points were toxicity and response.
Management of chemoperfusion
At the day of intervention the patients received 74 mg dolasetron
and 500 mg prednisolone i.v. (between 0700 and 0800 h Greenwich
Mean Time, GMT). A 1.5 l dose of a full electrolyte solution (with
20 mval potassium chloride) was administered subsequently by i.v.
infusion over 2 h. Transcutaneous catheterization of the right
femoral artery was carried out subsequently using a 4-french cathe-
ter containing a coaxial micro-catheter. Superselective visualization
of the tumour-feeding vessel and assessment of its volume capacity
using ﬂuoroscopy and a contrast medium were performed. It never
has been necessary to perform a provocation test because angiogra-
phy in these areas usually reveals enough information. Then,
150 mg m
72 cisplatin (maximal absolute dose 300 mg, lowest dose
225 mg) suspended as mentioned above (maximal amount of ﬂuid:
60 ml, smallest amount 45 ml) was infused with controlled pres-
sure via a hand-held syringe. In all cases, stasis of ﬂow inside the
peripheral capillaries of the tumour could be noticed via ﬂuoro-
scopy (Figures 3 and 4). For analgesia, 0.1 to 0.4 mg fentanyl
and 1 to 2.5 mg droperidol were delivered i.v. before start of ther-
apy. In cases of toothache, mainly observed during perfusion of the
maxillary artery, 1 ml of a 1:10 diluted 1% lidocain-HCl injection
into the perfused artery was able to block the pain. With a delay of
10 s, an i.v. infusion of 9 g m
72 sodium thiosulphate was given in
parallel. After the end of the chemoperfusion no more sodium
thiosulphate was given. Application of the cisplatin suspension
was ﬁnished a maximum of 3 h after preparation. One thousand
millilitres of full electrolyte solution with 20 mval potassium chlor-
ide was infused again (i.v. over 5 h, subsequent to treatment).
Administration of 500 mg prednisolone i.v. was repeated between
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Table 1 Patient and tumour characteristics, response data after ﬁrst cycle of both the study and the control groups. Performance status according to
ECOG (Oken et al., 1982), tumour classiﬁcation according to UICC (Sobin and Wittekind, 1997)
Group treated with chemoembolization
(cisplatin suspension)
Group treated with chemoperfusion
(cisplatin solution)
Age
(years) Sex
Performance
status
TNM classiﬁcation/
stage Response
Age
(years) Sex
Performance
status
TNM classiﬁcation/
stage Response
1 61 M 0 T3N1M0/III SD 66 M 0 T2N0M0/II SD
2 50 F 0 T4N0M0/IV PR* 66 M 1 T4N2M0/IV SD**
3 57 F 1 T4N0M0/IV PR 62 M 0 T2N0M0/II SD
4 68 M 1 T4N2M0/IV SD 63 F 1 T4N2M0/IV SD
5 81 M 2 T2N0M0/II PR 64 M 1 T2N0M0/II SD
6 64 M 2 T4N2M0/IV PR 73 M 1 T4N2M0/IV SD*
7 52 M 1 T4N2M0/IV SD* 63 M 0 T4N2M0/IV SD
8 81 F 2 T2N0M0/II CR 63 F 0 T4N2M0/IV SD
9 54 M 0 T4N0M0/IV PR* 48 F 0 T4N2M0/IV PR
10 53 F 1 T4N1M0/IV CR 62 M 0 T4N2M0/IV SD
11 57 M 0 T4N2M0/IV CR 49 F 0 T2N0M0/II SD
12 48 F 0 T2N0M0/II CR 51 F 0 T1N0M0/I PR
13 41 M 1 T2N0M0/II SD 53 M 0 T4N2M0/IV PR
14 65 M 1 T4N1M0/IV PR 59 F 0 T4N1M0/IV PD
15 66 M 2 T3N2M0/IV PR* 68 M 1 T4N1M0/IV SD
16 62 M 1 T4N2M0/IV SD 45 M 1 T2N0M0/II CR
17 88 M 2 T4N0M0/IV SD 70 F 1 T4N0M0/IV SD
18 57 F 1 T4N2M0/IV PD* 63 M 2 T4N0M0/IV PR
19 62 M 0 T4N2M0/IV CR 62 M 1 T4N0M0/IV SD
20 64 M 2 T4N2M0/IV PR* 55 M 2 T4N2M0/IV SD
21 57 M 1 T2N0M0/II CR 62 F 1 T1N0M0/I CR
22 47 M 0 T3N0M0/III PR 64 M 1 T3N2M0/IV CR
23 48 F 0 T2N0M0/II PR 67 M 0 T4N0M0/IV SD
24 59 F 2 T4N0M0/IV SD 63 M 0 T2N0M0/II CR
25 50 M 1 T4N1M0/IV PR* 48 M 0 T3N1M0/III PR
26 59 M 0 T4N1M0/IV SD 86 M 2 T4N1M0/IV PR
27 71 M 0 T1N0M0/I CR 75 M 2 T4N1M0/IV PR
28 65 M 2 T4N0M0/IV PR 56 F 2 T3N0M0/III PR**
29 41 M 0 T4N2M0/IV PR 56 M 0 T4N0M0/IV PR
30 77 M 0 T1N0M0/I CR 67 F 1 T4N0M0/IV PR
60.2+11.5 years 22 M
8F
0( n=12)
1( n=10)
2( n=8)
Stage I (n=2)
Stage II (n=6)
Stage III (n=2)
Stage IV (n=20)
8C R
13 PR
8S D
1P D
61.6+8.8 years 20 M
10 F
0( n=14)
1( n=11)
2( n=5)
Stage I (n=2)
Stage II (n=6)
Stage III (n=2)
Stage IV (n=20)
4C R
10 PR
15 SD
1P D
CR=complete remission; PR=partial remission; SD=stable disease; PD=progressive disease. Patients with one * received one repetition, those with two ** received two
repetitions of intra-arterial chemotherapy.
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3 days depending on local swelling. The day after intervention, the
patients were hyperhydrated with 3000 ml of a two-third electro-
lyte solution, received a thrombosis prophylaxis with heparin
S.C. (and dolasetron i.v., if necessary). Routine analgesia was given
with metamizol drops.
In the control group treated with a cisplatin solution, management
was very similar. No prednisolone was given, 150 mg m
72 cisplatin
was dissolved in 500 ml 0.9% saline solution and was perfused with
controlled pressure (2 ml s
71). Perfusion took about 5 min.
RESULTS
Chemoembolization was carried out 37 times in the 30 patients. In
ﬁve patients, there has been one repetition according to the study
plan; in patient no. 7 the tumour was so large that good remission
of the embolized part had to be assessed as overall stable disease
and repetition seemed to be promising, and in the only patient
with progression a desperate attempt was made by repetition.
Duration of injection at the end of neuroradiologic intervention
was between 60 and 90 s. Toleration of chemoperfusion was good
and the dosage of analgetics sufﬁcient. There have been two
complications of transcutaneous femoral catheterization: 6 days
after intervention, a patient (no. 11) suffered from a scrotal haema-
toma, which was treated conservatively and experienced resorption
after 15 days; one patient (no. 28) showed signs of embolism of the
left leg at the day of intervention. For three years since, he had an
aortofemoral prosthesis. Treatment with heparine was quickly
successful.
In the control group, there have been 35 interventions in 30
patients. In three patients, there has been repetition of cycles
(once two cycles, twice three cycles). The two patients with three
cycles refused surgery and radiation; one of them with stable
disease died due to heart failure, the other patient with partial
remission is alive and well 9 months after the end of treatment.
In one patient (no. 27), there has been an arterial occlusion in
the right leg which could be treated successfully without seque-
lae.
Remissions after one cycle are shown in Table 1. The response
rate (CR+PR) in the study group was 21/30 (70%). The tumours
of patients classiﬁed as stable disease showed reduction of tumor
mass of about 30%, large areas of necrosis and regressive altera-
tions in CT. The response rate in the control group was much
less pronounced (14/30=46.7%). Tumours classiﬁed as stable
disease showed less regressive alterations in CT.
The systemic and local side-effects of both groups are listed in
Table 2. In comparison with the regime using a cisplatin solution,
there have been less nausea, sideroemia, increase of hepatic
enzymes and no alopezia in the study group. Slight hyperglycaemia
up to 140 mg dl
71 vanished after 6 days. Systemic toxicity was
very low in both groups. There have been no grade III or IV toxi-
cities at all. Six and eight patients, respectively, showed no
measurable side-effects.
The local symptoms of pain and swelling combined with a non-
febrile leucocytosis (up to 19 000 mm
3) were similar to the known
‘post-embolization syndrome’. These symptoms were seen mainly
or exclusively in the study group. Swelling of the cheek and the
tongue was soft and vanished after 10 days. If swallowing was
impaired, a gastric tube secured enteral nourishment. Moderate
pain (grade II) was treated with metamizol and tramadol drops
and, if painful superinfection in swollen epidermolytic areas of
the oral mucosa was noticed, an oral antibiotic (clindamycine)
was prescribed for 5 days. Leukocytosis was not treated and
normalized after 10 days. Ward stay lasted between 3 and 17 days
(mean: 9.1 days) which was necessary for ﬁnancing this interven-
tional procedure under the conditions of German hospital
regulations. Although the patients of the control group showed
much less local symptoms, ward stay had to be extended up to 6
days for the same reason.
There have been ﬁve local complications in the study group
resulting from embolization of branches of tumour-feeding vessels
as perfusion of the deep temporal arteries during embolization of
the right maxillary artery (patient no. 3). A circumscribed necrosis
in the temporal muscle with temporary limitation of mouth open-
ing and a paralysis of the facial nerve both resulted. Limitation was
over 4 weeks later, recovery of nerve function took 3 months. Two
other patients (nos. 17 and 24) suffered from temporary facial
paralysis due to perfusion of the geniculate ganglion via the medial
meningeal artery. The tumours had to be embolized via the maxil-
lary artery in both cases. In two patients (nos. 10 and 11) skin
areas of the cheek and the chin were additionally embolized and
developed necrosis. This did not cause harm to the patients
because these skin areas had to be resected during the operation
in healthy margins.
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Figure 3 Angiographic ﬁlm before chemoembolization. Tumour blush in
the sublingual area.
Figure 4 Angiographic ﬁlm following chemoembolization using the aqu-
eous crystal suspension of cisplatin via the lingual artery. Occlusion of the
tumour-feeding vessels.
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(2), 196–202In the study group, 21 patients were operated on. Patients clas-
siﬁed N0 underwent elective neck-dissection, patients classiﬁed
N1–3 modiﬁed radical neck-dissection. In three specimens, there
has been evidence of complete histological remission (pT0), very
small tumour tissue could be found in ﬁve specimens (pT1). There
have been one pT2 and 12 pT4 specimens. Two patients refused
further treatment, three patients were radiated after chemoemboli-
zation, four other patients were in too bad general condition for
either surgery or radiation. To date, there has been one patient
(no. 1) with distant metastasis to the vertebra 2 months after the
end of treatment who was operated on for palliation. Four patients
are dead. One patient (no. 17) died 1 week after the operation due
to heart failure, two patients (nos. 5 and 6) died several days after
the end of radiation, one patient (no. 15) died due to extreme
tumour cachexia.
In the control group, 24 patients were operated on with the
same criteria for neck surgery. Twice, there has been complete
histological remission (pT0), ﬁve times pT1, seven times pT2, twice
pT3 and eight times pT4. One patient was radiated after
chemotherapy, two patients refused further treatment, three
patients were in too bad a general condition for either surgery or
radiation. There have been two local relapses and one regional
relapse to date. One patient (no. 11) could be treated successfully
by salvage operation, one patient (no. 19) is treated to date with
low-dose methotrexate for palliation, one patient (no. 6) died 10
months after the end of treatment. There have been three second-
ary tumours (patient no. 10 with lung cancer, patient no. 14 with a
maxillary tumour, and patient no. 28 with a hypopharyngeal
tumour). Patient no. 10 died 12 months after the end of treatment,
the others are treated to date. One patient (no. 2) died after the
third chemotherapy cycle, one patient (no. 18) died 12 days after
the operation, both due to heart failure. In sum, four patients
are dead to date.
DISCUSSION
Intra-arterial chemoembolization was mainly used as treatment of
primary hepatocellular carcinomas and liver metastases. To date,
embolization was achieved either with encoated drugs (microcap-
sules) (Kato et al, 1996) or with concomitant delivery of
embolizing substances like polyvinyl alcohol, lipiodol, albumine,
degradable starch microspheres using mixtures, sometimes with
several drugs (Tellez et al, 1998; Vogl et al, 2000; Yamamoto et
al, 2000). These protocols have certain advantages: microcapsules
provide good reproducibility of the product with good control of
particle diameter, and a pharmacologically adjusted time of drug
release. The embolizing substances occlude the tumour-feeding
vessel for a certain time and stop intratumoural ﬂow before being
dissolved. These advantages compete with serious drawbacks:
production of microcapsules is a complicated and expensive tech-
nical process, often necessitating 900% more encoating material
than drug. The patient is stressed with additional substances which
is also a drawback of the combination of several drugs (polyche-
motherapy) justiﬁed mainly in palliative treatment. In the case of
auxiliary substances (it may be a viscous suspension like lipiodol
or different larger microparticles), there is also the problem of
production taking much costs, time, and effort. It is obvious that
any embolizing agent would be extremely dangerous in the head
and neck area. Anastomoses to the ophthalmic artery and arteries
feeding nerval structures must not be occluded, not even a short
time. Even short complete occlusion of vessels like the facial or
lingual artery would have the risk of necrosis of important organs
which is intolerable. The amount of the embolizing agent cannot
be completely assessed before the action of delivery because the
exact diameter of the perfused vessels and capillaries is not known
and delivery has to be continued until occlusion is achieved. In the
head and neck area, complete occlusion should be aimed at very
cautiously. These are the reasons why chemoembolization was used
rarely in the past. According to the body of literature, only 54 head
and neck SCC patients were treated using embolization protocols
in Japan and China in a period of more than 14 years (Okamoto
et al, 1985, 1986; Kato et al, 1996; Tomura et al, 1996; Konno et al,
1998; Tomura et al, 1998; Li et al, 1999).
In contrast, the new technique presented has many principal
advantages. It provides a monocomponent (cisplatin as made avail-
able by the producer) which serves as microembolizing agent itself.
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Table 2 Systemic and local side-effects and complications of both the study and the control groups. Grades
according to WHO (Miller et al., 1981)
Grade I Grade II
Cisplatin suspension Cisplatin Cisplatin suspension Cisplatin
Toxicity (embolization) solution (embolization) solution
Systemic Nausea (n)2 6 1 3
Hypokalaemia (n)6 5 0 0
Sideroemia (n)2 6 0 0
Hyperglycaemia (n)9 5 0 0
Hyperuremia (n)1100
Serum creatinine (n)3 3 0 0
Hepatic enzymes (n)3 5 0 0
Alopezia (n)0 2 0 0
Post-embolization Pain(n)2 0 8 2 0
syndrome Leucocytosis (n)1 5 0 0 0
Swelling (n)7 2 0 0
Local complications Cisplatin suspension
(embolization): (n)5
(3 facial paralyses,
2 skin necrosis)
Cisplatin solution: (n)0
Cather-related Cisplatin suspension
(embolization): (n)2
Cisplatin solution: (n)1
No measurable Cisplatin suspension
toxicity (embolization): (n)6
Cisplatin solution: (n)8
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crystalline precipitates have a rather regular diameter of 368 mm
and agglomerate to maximum 30650 mm particles, thereby allow-
ing periphery embolization of intratumoural capillaries but vessels
with a larger diameter (mainly the facial or lingual artery) are
spared. The time of dissolution of these crystals in the arterial ﬂow
at body temperature is likely to be about 20 to 30 min as having
been assessed at 408C (Kristjansson et al, 1988). The demonstrated
tumour response rate is a clear indicator of better effect than
achieved by a solution. It can be subsumed that the reason for this
rate is not only the higher concentration of the drug in the suspen-
sion but the presumed slower intratumoural dissolution of the
crystals.
Superselective administration of the agent into the tumour-feed-
ing vessel is mandatory. Larger vessels normally cannot be
occluded. The observed accidental occlusion of the deep temporal
arteries must have been caused by their individual small diameter.
Not only is the response better but the systemic acute toxicity is
lower. This may have the following reasons. A higher intratumour-
al concentration resulting from a higher ﬁrst-pass or trapping effect
may be likely. A technical detail contributes to the favourable ﬁnd-
ings of higher response and less systemic toxicity. Intraarterial
delivery of the smaller amount of ﬂuid (maximum 60 ml aqueous
cisplatin suspension) using a hand-held syringe results in better
time management with consideration of the parallel intravenous
infusion of sodium thiosulfate. The large amount of ﬂuid used
for the cisplatin solution (500 ml) sometimes led to spasms of
the vessel and interruptions of perfusion. Duration of administra-
tion was longer (5 min), the pumps used provided a standardized
ﬂow but were clumsy in operation. Now the capacity of the vessel
could be assessed by hand-controlled injection of saline ﬁrst,
followed by injection of the suspension with the same pressure.
The injection could be executed quickly in less than 2 min without
reﬂux of blood and possibly sodium thiosulphate, a good ﬂow
could be achieved with full exposure of the tumour bed to cispla-
tin. Sodium thiosulphate has reached the periphery when cisplatin
arrived there.
The local side-effects could easily be overcome and posed no
problems for maxillofacial routine care.
There are no presently available multi-agent chemotherapies
with comparable high response rates after one cycle and similar
low rates of acute side-effects. Main problem of the presented
method is potential facial paralysis which may occur in case of
perfusion of the maxillary artery or the external carotid artery. This
can be avoided by excluding patients where this is expected and
using the cisplatin solution instead where no embolizing effect is
present.
To our knowledge, the only explicit attempts reported in litera-
ture, to suspend cisplatin in high concentration in saline were
carried out by a Japanese group (Kawakami et al, 1988; Ono et
al, 1989). They needed a control for investigating the effects of a
cisplatin-lipiodol suspension on the rat liver. As is common know-
ledge today, they found a higher afﬁnity of lipiodol to liver tissue.
The potential of the aqueous cisplatin suspension with its precipi-
tation of crystals was not recognized. Tsujimoto et al (1993, 1996)
used specially manufactured cisplatin microcrystals of less than
500 mm in diameter suspended in a mixture of sesame oil and
lipiodol. They investigated the toxicity of intraperitoneal adminis-
tration of that suspension in mice. The toxicity was equal to or
less than with a regular cisplatin solution. For preparation of the
infusion of a cisplatin solution, the manufacturer recommends
diluting the cisplatin dose to a maximal concentration of
1m gm l
71 (Trissel, 1998). At concentrations higher than
1m gm l
71 precipitation occurs and cisplatin is not dissolved
totally. The use of a concentrated injection seemed justiﬁed for
two reasons: the absolute dose of cisplatin remained the same as
in the well established settings of intra-arterial chemotherapy of
more than 300 head and neck cancer patients (Kova ￿cs et al,
1999; Robbins et al, 2000), and highly concentrated mixtures of
cisplatin with embolizing agents with same or larger particle
diameters were used for decades in the treatment of patients with
liver cancer and metastases (Tellez et al, 1998; Yamamoto et al,
2000). The high concentrations up to 10 mg cisplatin in 1 ml lipio-
dol (Yamamoto et al, 2000) or other embolizing agents were
empirically motivated and had no pharmacological foundation.
Dosages were much lower (maximum 100 mg m
72) than in the
present study. Using the method described in this study, the mono-
component as provided by the manufacturer could be used as
embolizing pharmacon without additional agents. Moreover, the
required small volume for rapid injection was achieved. Use in
the head and neck area proved to be feasible.
The combination of anti-neoplastic effect with microembolizing
features offered by the same anti-neoplastic pharmacon was made
possible by dispersing that pharmacon in an aqueous crystal
suspension. This new principle called ‘monocomponent chemoem-
bolization’ showed the ﬁrst good results in routine intra-arterial
chemoembolization of oral cancer patients and will be continued.
It may also be investigated in other indications.
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